The semaglutide autoinjector: what it is, how it works, and what people get wrong

Myth: the pen is complex and you need to be trained like a nurse

This is the worry that stops more people than almost anything else. In practice, Wegovy's autoinjector was designed specifically for self-administration at home, and the mechanism is straightforward once you have read the Patient Information Leaflet that comes with your prescription. You remove the cap, place the pen against your skin, press and hold. The injection fires automatically. There is no plunger to depress, no needle to manually insert, and no dose to measure, the pen is pre-set to the dose your prescriber has prescribed for this stage of your treatment.

What you do need to do: clean the injection site first (a quick wipe with a clean swab works fine), pinch a little skin if you are using the abdomen, hold the pen in place for around ten seconds after activation to make sure the full dose has been delivered, and check the inspection window to confirm it. That is the whole process. If you want to understand exactly how the Wegovy auto injector works before your first injection, the Wegovy pen injector page on this site walks through each physical step in detail. Most people find the anticipation is harder than the injection itself, that is genuinely the most common thing our prescribers hear from people on their first week.

One practical note on timing: if your injection day falls on a bank holiday or you are away, you have a short flexibility window around your usual day, the exact parameters are in the Patient Information Leaflet. It is worth checking this before a long weekend rather than guessing. Storage in the fridge (2–8°C) matters throughout; the precise room-temperature window if the pen is out of the fridge varies by product batch and is stated in the leaflet, not here.

Myth: the autoinjector format is the same regardless of which semaglutide product you have

It is not, and confusing them has real consequences. Wegovy (semaglutide 2.4 mg and, from 2026, 7.2 mg) is the product licensed in the UK for weight management. Ozempic is also semaglutide but is licensed for type 2 diabetes, the pens look broadly similar, the doses are different, and it is not a weight-loss medicine under UK licensing. Using the wrong product or the wrong dose is a clinical matter, not a formatting one.

The 7.2 mg single-dose Wegovy pen, approved by the MHRA on 14 April 2026, is a distinct device from the original 2.4 mg pen. It has an auto-dosing mechanism, a built-in covered needle, and locks after use. The MHRA's approval applies specifically to adults with a BMI of 30 or above; it is not licensed for the cardiovascular indication or for people below that BMI threshold. Titration still starts at 0.25 mg and progresses under prescriber guidance, the high-dose pen is not a starting point.

For a broader overview of the semaglutide injection itself, including how semaglutide works as a GLP-1 receptor agonist and the trial evidence behind it, the semaglutide injection page covers the mechanism and the clinical background, including the STEP 1 trial data published in the New England Journal of Medicine. You can also find more detail on the device itself, including needle size and how the dose window works, on the semaglutide pen injector page.

How the pen fits into a treatment that needs clinical oversight

The autoinjector is a delivery device. The treatment is the semaglutide, and the treatment requires a prescriber. Under UK licensing, Wegovy is indicated for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. None of that is self-certified, the prescriber assesses it.

Side effects from semaglutide are mostly gastrointestinal: nausea, loose stools, constipation, acid reflux and reduced appetite are the most commonly reported. They tend to be most noticeable in the first week or two at a new dose and settle for most people. Severe or persistent stomach pain that spreads to the back is different, that warrants urgent medical attention and may indicate pancreatitis, a known though infrequent risk highlighted in the MHRA's January 2026 Drug Safety Update for GLP-1 medicines. It is also worth reading about what happens if you overeat on Wegovy, since pushing past your appetite signals can affect how you feel and how well the treatment works. The Yellow Card scheme is where patients can report any suspected side effects.

Used pens should go into a sharps container, the lid seals, and full containers can be returned to a pharmacy or collected by your local council. It is a small habit that matters.

If you are exploring weight-loss treatment options more broadly, the weight-loss treatment overview covers what is currently licensed in the UK and how the options compare. And if you are ready to talk to a prescriber about whether Wegovy is clinically appropriate for you, the place to start is a free consultation with the nume team, reviewed the same working day by a GPhC-registered Independent Prescriber, with same-day dispatch if approved.